✦ LIBER ✦

Safety profile and clinical activity of sifalimumab, a fully human anti-interferon monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study

✍ Scribed by Merrill, J. T.; Wallace, D. J.; Petri, M.; Kirou, K. A.; Yao, Y.; White, W. I.; Robbie, G.; Levin, R.; Berney, S. M.; Chindalore, V.; Olsen, N.; Richman, L.; Le, C.; Jallal, B.; White, B.

Book ID: 124089934
Publisher: BMJ Publishing Group
Year: 2011
Tongue: English
Weight: 385 KB
Volume: 70
Category: Article
ISSN: 0003-4967
DOI: 10.1136/ard.2010.144485

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Biologic activity and safety of belimuma

Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus

✍ Richard Furie, William Stohl, Ellen M Ginzler… 📂 Article 📅 2008 🏛 BioMed Central 🌐 English ⚖ 914 KB

Efficacy and safety of secukinumab, a fu

Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial

✍ McInnes, I. B.; Sieper, J.; Braun, J.; Emery, P.; van der Heijde, D.; Isaacs, J. 📂 Article 📅 2013 🏛 BMJ Publishing Group 🌐 English ⚖ 471 KB

Phase I, double-blind, randomized, place

Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of NI-0401 (a fully human anti-CD3 monoclonal antibody) in patients with moderate to severe active Crohn's disease

✍ C. Janneke van der Woude; Pieter Stokkers; Ad A. van Bodegraven; Gert Van Assche 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 274 KB 👁 2 views

Background: NI-0401 is a fully human monoclonal antibody, which binds to the CD3 subunit of the T-cell receptor, causing modulation of T-cell activity. We investigated the safety and the ability to modulate the TCR-CD3 complex of NI-0401 in patients with active Crohn's disease (CD). Methods: A doub

A phase II, randomized, double-blind, pl

A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis

✍ Michael Yellin; Igor Paliienko; Andra Balanescu; Semen Ter-Vartanian; Vira Tselu 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 199 KB

493 Safety Profile and Signal of Efficac

493 Safety Profile and Signal of Efficacy of a Non-Fcr-Binding, Fully Human Anti-Cd3 Monoclonal Antibody in Patients with Moderate to Severe Crohn's Disease- Results of a Phase I/Iia, Double Blind, Placebo-Controlled, Randomized, Dose Escalation Study

✍ Christien J. van der Woude; Pieter C. Stokkers; Ad A. van Bodegraven; Gert A. Va 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 87 KB

Safety profile and clinical activity of

Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies in subjects with asthma

✍ Joseph M Parker; Chad K Oh; Craig LaForce; S David Miller; David S Pearlman; Che 📂 Article 📅 2011 🏛 BioMed Central 🌐 English ⚖ 361 KB